Latest News and Press Releases

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights...

Fréttatilkynning22. júlí 2024STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu Líftæknilyfjahliðstæðan kemur á markað um leið og einkaleyfi fyrir...

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously...

Alvotech (NASDAQ: ALVO) tilkynnti í dag að endurfjármögnun skulda félagsins væri nú lokið. Með því hefur félagið lækkað fjármagnskostnað og lengt lánstíma útistandandi skulda. Að endurfjármögnuninni...

REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...

Jákvæðar niðurstöður rannsóknarinnar sýna sambærilega klíníska virkni AVT03 og samanburðarlyfsins Prolia (denosumab) í sjúklingum Endapunktur var einnig uppfylltur í tveimur klínískum rannsóknum þar...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated...